CompanyHealthHardware
Abdera Therapeutics
Abdera Therapeutics is a precision oncology biotech engineering antibody-based radiopharmaceuticals that deliver therapeutic radioisotopes directly to tumor cells while sparing healthy tissue. Built around its proprietary ROVEr platform, the company is advancing ABD-147 in Phase 1 trials for small cell lung cancer and large cell neuroendocrine carcinoma, with a second program, ABD-320, on deck.
2021Founded
South San FranciscoHQ
$85.2MSeries B (latest tranche)
radiopharmaceuticalsoncologyprecision-medicineantibody-engineeringtargeted-alpha-therapybeta-emitters